Overview

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

Status:
Terminated

Trial end date:
2020-11-15

Target enrollment:

Participant gender:

Summary

This phase I/II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab and trabectedin may work better in treating patients with liposarcoma or leiomyosarcoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborators:

EMD Serono
National Cancer Institute (NCI)

Treatments:

Antibodies, Monoclonal
Avelumab
Trabectedin